Related Experiment Videos
Hypertrophic cardiomyopathy: prognosis with medical or surgical therapy
1Department of Medicine, University of California, San Diego School of Medicine, La Jolla 92093.
Insights
Hypertrophic cardiomyopathy (HCM) treatments vary, with some medical therapies showing limited survival benefits. Surgical intervention is effective for severe cases, offering prolonged relief for medically refractory patients.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) presents with variable clinical manifestations, complicating treatment strategies.
- Despite advances, understanding of HCM's natural history and therapeutic effects remains incomplete.
- Patient responses to medical management for HCM symptoms are inconsistent.
Purpose of the Study:
- To review current knowledge on hypertrophic cardiomyopathy (HCM) management.
- To evaluate the efficacy and safety of various therapeutic options for HCM.
- To identify areas requiring further research in HCM treatment and survival.
Main Methods:
- Review of existing literature on hypertrophic cardiomyopathy (HCM) over the past 30 years.
- Analysis of outcomes associated with medical therapies, including beta-blockers, calcium channel blockers (verapamil), and amiodarone.
- Assessment of surgical interventions for HCM, focusing on outcomes in medically refractory patients.
Main Results:
- Chronic beta-blockade shows no significant impact on long-term survival in HCM patients.
- Calcium channel blockade with verapamil demonstrates encouraging results but requires further confirmation and carries risks in severe cases.
- Amiodarone's beneficial effects on survival in HCM need additional investigation.
- Surgical myectomy is the preferred treatment for medically refractory HCM with outflow tract obstruction, offering low operative risk and sustained symptomatic improvement.
Conclusions:
- Current medical therapies for hypertrophic cardiomyopathy (HCM) have limitations regarding long-term survival benefits.
- Surgical treatment is a viable and effective option for severe, medically refractory HCM with outflow tract obstruction.
- Further research is essential to clarify the long-term impact of calcium channel blockers, amiodarone, and surgical interventions on HCM patient survival.
Abstract:
Over the past 30 years, knowledge of the natural history and effects of therapy in patients with hypertrophic cardiomyopathy has expanded greatly, but progress has been hampered by its variable patterns of expression. Many but not all patients show symptomatic improvement with medical treatment. Chronic beta blockage does not appear to affect long-term survival, whereas results with calcium channel blockade by verapamil have been encouraging; however, they await confirmation, and verapamil may be hazardous in some patients with severe left ventricular (LV) outflow tract obstruction and elevated LV end-diastolic pressure. Reported beneficial effects of amiodarone on survival also require further study. Surgical therapy has become the treatment of choice for medically refractory patients with proven outflow tract obstruction. In several centers, the operative risk is low, and long-term follow-up demonstrates prolonged symptomatic relief. It is hoped that work currently underway will provide more definitive information on the long-term effects of the role of calcium channel blockers, antiarrhythmic medications, and the long-term effects of surgical therapy on survival of patients with this disorder.